The ability to metastasise can reasonably be regarded as the single most important characteristic of the vast majority of malignant tumours. It is also the least understood. Purely descriptive accounts of some of the most critical phases of the metastatic process are still lacking, and knowledge of the underlying mechanisms is rudimentary. Some advances are, however, being made and this review is concerned with work reported (for the most part) in the last decade which pertains to the two major metastatic pathways -lymphatic and haematogenous spread. The emphasis is on human studies but experimental data are included wherever necessary.
Spread of tumour in the lymphatic system
The lymphatics form the major route of dissemination for carcinomas and for many melanomas, neuroblastomas and malignant teratomas. Lymphborne metastases from sarcomas are uncommon but are most likely to be encountered in alveolar and embryonal rhabdomyosarcomas, synoviosarcomas and epithelioid sarcomas.'
PENETRATION INTO THE LYMPHATIC SYSTEM
Primary tumours do not contain lymphatic vessels and the main points of entry of malignant cells into the lymphatic system are lymph capillaries near the growing edge of the neoplasm. The microanatomical location and the density of lymphatics vary considerably in different tissues and are important determinants in the eventual incidence and distribution of regional lymph node metastases. Small lymph vessels resemble blood capillaries in their histological structure, consisting of endothelial cells linked by various types of interendothelial junctions and bounded externally by a basement membrane which is frequently discontinuous. Lymphatics from different parts of the body vary in the numbers and organisation of interendothelial junctions and the *An expanded version of a lecture given at the Armed Forces Institute of Pathology, Washington DC on June 16, 1981. Accepted for publication 29 June 1982 arrangements of the basement membrane2; regional differences of this kind may in part determine the ease with which the lymphatic system is invaded at certain anatomical sites.
The process whereby tumour cells penetrate local lymphatic vessels is ill-documented. The scanty information available is based on experimental studies with various types of tumour cells inoculated into the footpads of rats. 34 Serial examination of tissues in the electron microscope indicates that the injected tumour cells first align themselves along the lymphatic channels. They then appear to protrude cytoplasmic processes between endothelial cells and migrate through interendothelial junctions, either as single cells or as small clumps. Damage-to contiguous endothelium and perivascular collagen fibres is usually minimal or absent. Lymphatics in the rat footpad appear to be almost devoid of basement membrane, and the endothelium provides the sole (and manifestly ineffective) barrier to be traversed by invading tumour. The processes whereby neoplastic cells breach the endothelial layer are unknown, but possible factors include mechanical pressure exerted by motile tumour cells and the local release of substances which cause endothelial retraction or inflict minute lesions on or near the junctional complexes.
Once tumour cells, singly or in clumps, have crossed the lymphatic wall, they enter a low-pressure flow system in which circulation is maintained by a combination of intrinsic contractions of the lymphatic walls and extra-lymphatic pressure exerted by the movements of local muscles and transmitted arterial pulsations. INTRANODAL TUMOUR: SOME LATE EFFECTS As the lymph node is replaced by metastatic tumour, lymph perfusion through the pulp will diminish and tumour cells will be carried to other nodes in the same or contiguous anatomical groups. Various complications of intranodal lymphatic obstruction will ensue. Retrograde lymph flow can cause tumour cells to be carried to more distant parts of the lymphoid system where they give rise to anatomically anomalous deposits of metastatic tumour. Retrograde flow is also responsible for spread of tumour cells, still within lymphatics, to sites outside the conventionally defined lymphoid system. Necropsy studies of disseminated breast cancer have shown widespread lymphangitis carcinomatosa in the visceral and parietal pleura and lung parenchyma. '3 Similar lymphatic spread may occur in the liver. Local obstruction of lymphatic vessels will lead to oedema and, in the case of diaphragmatic lymphatics, to ascites -though the relative importance here of decreased lymphatic absorption and increased production of intraperitoneal fluid is uncertain. "' Tumour cells may disseminate from lymph nodes into the vascular system at several points. They include small intranodal vessels; extranodal vessels invaded by metastatic tumour which has breached the nodal capsule; lymphaticovenous communications opening up in the involved lymph node; and the thoracic duct.
Such spread is usually regarded as a late event, occurring when most or all of a lymph node is replaced by metastatic tumour. The basis for this assumption is unclear, and there are no a priori reasons why intranodal tumour cells should not disseminate further in the blood stream at an earlier phase.
The localisation of nodal metastases is largely determined by the local anatomy, though anomalies sometimes arise. Normal pathways of lymphatic drainage may be modified by previous radiotherapy and major surgery. Retrograde spread of intralymphatic tumour has already been noted. Certain aspects of the basic anatomy at some sites are still unclear, and the continuing discussion as to whether each breast quadrant does or does not have a consistent and specific pattern of lymph drainage provides one example.'6 The more important question of predicting whether nodal metastases will develop -as opposed to forecasting their anatomical distribution -is complex and speculative, and falls outside the scope of this short account.
Spread of tumour in the vascular system
Sarcomas disseminate predominantly by the blood stream, and melanomas, neuroblastomas and malignant teratomas spread almost equally in the blood and lymphatic systems. Haemic dissemination is an important and often underestimated metastatic route for carcinomas, 7 even though lymphatic spread predominates in many instances.
PENETRATION INTO THE BLOOD VASCULAR SYSTEM
Malignant cells enter the circulation by invading blood vessels situated either within the substance of the main tumour mass or near its advancing edge; they may also gain access indirectly through the lymphatic system -see earlier. The vasculature of tumours originates from pre-existing vessels in the tissue of origin and from newly formed vessels derived from them. The stimuli for angioneogenesis within tumours are unclear, but they are likely to stem from host sources (especially local lymphocytes) as well as from neoplastic cells themselves. 8 9 Such vessels are extensive and often imperfectly formed with irregular lumina, discontinuous and sometimes abnormal endothelium, defective basement membrane and (in larger vessels) scanty or absent perivascular connective tissues. Sarcomas often contain large blood-filled channels wholly or partly lined by malignant cells which can shed direct into the blood. Vascular endothelium in experimental tumours is capable of intense proliferative activity20
and, in clinical material, endothelial hyperplasia is a distinctive feature of high grade astrocytomas and (to a lesser extent) other primary intracranial neoplasms. Similar vessels are seen in some brain metastases, and they have also been described in the very rare extracranial metastases from gliomas in sites such as cervical lymph nodes.2' Despite the extensive vasculature, the rapid endothelial turnover and the overall high perfusion rate in many tumours, regional perfusion with them is frequently defective. Many of the abnormal vessels are excessively permeable and the interstitial compartment in most tumours is large. 22 The accumulation of pericellular fluid is enhanced by the absence of any intrinsic lymphatic drainage. Regions of necrosis within a tumour, and the accumulation of oedema fluid and fibrin at its edges, are at least in part explained by such circumstances. Necrosis is often marked in rapidly proliferating tumours with a large cell loss fraction, and such tumours, which are sometimes very small, have a notably high metastatic rate. Examples include small cell anaplastic carcinomas of the bronchus, melanomas, malignant teratomas and choriocarcinomas. There is some experimental evidence that local necrosis favours the detachment of cells from the growing tumour mass. 23 Normal blood vessels at or near the edge of the tumour are fewer and less readily penetrated by invading cells, but they represent the major route for haemic dissemination. 
Some quantitative data on the release of cells into the circulation from transplanted tumours are available from studies in mice" and rats,"0 and extensive work has been done on the fate of tumour cells injected intravenously in experimental animals."3' Such manoeuvres are convenient but artificial, in that they by-pass the essential phase of vascular invasion, and extrapolation of results to the metastatic process as it really exists is often questionable.
ARREST OF CIRCULATING TUMOUR CELLS
The morphological changes which ensue when tumour cells are arrested in the circulation were meticulously described in both clinical and experimental material in the early part of this century. In brief, tumour cell emboli in small vessels of the lungs, liver and other tissues stick to vascular endothelium where 36-45. likely to remain dormant; but the whole question of tumour dormancy remains obscure and the relative contributions of neovascularisation, tumour cell kinetics and host inflammatory and immune responses are almost totally speculative.
Once a nidus of tumour cells starts to expand it will infiltrate surrounding tissues in the same way as a primary neoplasm. The topic of tumour invasion falls outside the scope of this review, but one point should be noted -the growing evidence that host elements play an important role in the invasive process. In soft tissues, for example, it is local polymorphs, macrophages and fibroblasts near the tumour's growing edge which elaborate potent proteases. Comparable activity in the tumour cells themselves may be less or even absent4"50 though the operation of functional interactions between neoplastic cells and the tumourassociated stromal components is virtually certain. A comparable situation is seen when tumour cells are invading cortical bone: most bone destruction appears to be mediated by osteoclasts which are activated locally by both the tumour and the adjacent stroma.5053
Human tumours implanted as xenografts in immune-depressed animals are unsatisfactory models for studying local growth patterns. Irrespective of their previous clinical behaviour, such tumours form slowly growing lesions enclosed in fibrous tissue.
Neoplastic infiltration of local tissues, and metastasis, are both exceptional events. 54 The later stages of metastatic development need no detailed comment. Growth is usually progresive and, in some instances, doubling times have been shown to be greater than those of the primary tumour by a factor of 15 to '." Spontaneous arrest and regression of metastases are exceptionally rare'" and the underlying mechanisms are unknown. Most established metastases resemble their parent tumour in histological structure though, as in lymph nodes, marked dedifferentiation may lead to diagnostic problems for the pathologist. Identification of small lesions, especially in the liver and bone marrow, is aided by immunoperoxidase techniques and the widely distributed epithelium membrane antigen (EMA) is proving particularly useful.'256
Localisation of metastases
The distribution of lymph-borne metastases was discussed earlier and this final section is concerned with the localisation of blood-borne tumour. Some of the factors implicated are summarised in Table 2 .
The large pulmonary and hepatic vascular beds form the first and quantitatively most important filters for trapping circulating tumour cells, and the lungs and liver are the two commonest sites of haemic metastases. A third set of primary filters is probably provided by the terminations of Batson's paravertebral venous plexuses in parts of the axial skeleton.57 The importance of these plexuses as a metastatic pathway is disputed'7 and the situation is complicated as blood-borne tumour cells may reach the skeleton by at least two routes -directly through the paravertebral venous plexuses and also by the systemic circulation through the peripherally directed branches of the nutrient arteries. Tumours also invade contiguous bone by direct extension. Bross and his colleagues58 59 have proposed that the lungs and liver act as "key generalising sites" from which subsequent metastases are generated. Their data are group.bmj.com on January 12, 2018 -Published by http://jcp.bmj.com/ Downloaded from now extensive and are derived from large numbers of tumours arising at many sites, but the limitations of the hypothesis need to be borne in mind. The information is based on necropsy findings and thus reflects advanced, often long-standing, end-stage disease which has been previously treated. Lymphatic dissemination is not included and it was noted earlier.
that parenchymal organs such as the lungs and liver can be extensively infiltrated by lymph-borne tumour from a distant primary in the form of lymphangitis carcinomatosa. It is self-evident that a proportion of tumour calls initially trapped in the primary capillary filters can escape. In the early stages, some cells may squeeze through capillary lumina and enter the systemic circulation while others traverse vascular shunts. Later, tumour cells may be released from established foci in these regions; Willis'" has stressed that such deposits may be minute.
The non-random distribution of systemic metastases outside the lungs, liver and parts of the axial skeleton is one of the oldest observations of tumour pathology. It still remains true, but certain features may be noted. Detailed necropsies on some patients with tumours such as carcinoma of the breast, melanoma and some soft tissue sarcomas, show that metastases can develop at almost any site. Metastases in the spleen are not the rarities they are sometimes made out to be. 7 Secondary deposits in the adrenals are probably drawn from a wider spectrum of primary tumours than is often supposed.60 Furthermore, metastatic patterns from any one tumour type are not immutable. Necropsy studies are now showing that squamous carcinomas of the head and neck quite frequently metastasise to distant sites,6' that osteosarcomas may also spread to extrapulmonary tissues such as lymph nodes, abdominal viscera and other parts of the skeleton62 and that the distribution of metastases from breast cancer may be changing as a result of treatment.63 Some of the factors that are implicated in the localisation of blood-borne metastases have been summarised in Table 2 . The traditionally disparate elements of the "haemodynamic" and "soil and seed" theories of metastatic localisation, associated with James Ewing and Stephen Paget, have been deliberately merged as the distinction seems futile.
Apart from the lungs and liver, no wholly consistent association has yet been established between the organ distribution of systemic bloodborne metastases and regional haemodynamic characteristics such as blood volume, blood flow and transit times within a specific organ. 6 There is growing evidence that human tumours are heterogeneous with respect to features such as karyotypes and DNA content, the presence of hormone receptors. antigenic determinants and ceHl surface constituents, pigment synthesis, drug sensitivity, in vitro growth characteristics and growth as xenografts in immune-suppressed mice.8287 Similar differences, albeit less clearly defined, have been described for some properties from primary and metastatic tumours in man. Whether such characteristics can be associated with specific genotypic sub-populations with an enhanced capacity to metastasise is wholly unknown, and the need to consider the probable operation of several different, non-exclusive metastatic mechanisms should require no special pleading." 
